The stock price of Celldex Therapeutics Inc. (NASDAQ: CLDX) has plunged by -2.05 when compared to previous closing price of 37.02, but the company has seen a -5.89% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-09 that The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is It Worth Investing in Celldex Therapeutics Inc. (NASDAQ: CLDX) Right Now?
The stock has a 36-month beta value of 1.60. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CLDX is 62.84M, and at present, short sellers hold a 10.74% of that float. On April 26, 2024, the average trading volume of CLDX was 935.80K shares.
CLDX’s Market Performance
CLDX’s stock has seen a -5.89% decrease for the week, with a -11.65% drop in the past month and a -2.89% fall in the past quarter. The volatility ratio for the week is 4.06%, and the volatility levels for the past 30 days are at 4.08% for Celldex Therapeutics Inc. The simple moving average for the past 20 days is -8.57% for CLDX’s stock, with a 5.65% simple moving average for the past 200 days.
Analysts’ Opinion of CLDX
Wells Fargo, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $27. The rating they have provided for CLDX stocks is “Equal Weight” according to the report published on November 10th, 2023.
Wells Fargo gave a rating of “Underweight” to CLDX, setting the target price at $21 in the report published on August 22nd of the previous year.
CLDX Trading at -13.56% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.82% of loss for the given period.
Volatility was left at 4.08%, however, over the last 30 days, the volatility rate increased by 4.06%, as shares sank -13.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.81% upper at present.
During the last 5 trading sessions, CLDX fell by -5.89%, which changed the moving average for the period of 200-days by +0.69% in comparison to the 20-day moving average, which settled at $39.38. In addition, Celldex Therapeutics Inc. saw -8.57% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -20.64 for the present operating margin
- 0.56 for the gross margin
The net margin for Celldex Therapeutics Inc. stands at -19.54. The total capital return value is set at -0.33. Equity return is now at value -37.45, with -34.56 for asset returns.
Based on Celldex Therapeutics Inc. (CLDX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -42.21.
Currently, EBITDA for the company is -139.03 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 334.68. The receivables turnover for the company is 1.52for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.87.
Conclusion
To sum up, Celldex Therapeutics Inc. (CLDX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
